JAK inhibitors (ruxolitinib, baricitinib, tofacitinib), interferons (interferon alpha, interferon beta), PD-1 and PD-L1 inhibitors (cemiplimab, nivolumab), selective immunosuppressants (emapalumab, sirolimus, mycophenolic acid), and aminoquinolines (hydroxychloroquine, chloroquine) were found to be involved in the enriched pathways by the genes related to instruments for SBP, for DBP, for WHR, and for T2DM. This evidence concerns the gene PDCD1 and type 2 diabetes mellitus.